Loading organizations...
Loading organizations...
Medisafe is a technology company.
Medisafe delivers a digital medication engagement platform empowering patients to manage their treatment. It offers capabilities for enhancing adherence, facilitating care coordination, and providing crucial support for patients and caregivers. Technically, it integrates Just-in-Time-Interventions (JITI) and a Care Integration Engine for personalized guidance.
Founded in 2012 by brothers Omri and Rotem Shor, Medisafe's origin stemmed from a personal family health crisis. Their diabetic father's accidental insulin overdose due to medication miscommunication highlighted a widespread problem. This insight drove the Shor brothers to create a platform assisting patients with complex prescription schedules and improving healthcare collaboration. Rotem Shor is CTO and Co-founder.
Medisafe's platform serves patients for medication management, also supporting pharmaceutical and life sciences partners. The company's mission is to empower individuals to seamlessly navigate treatment, aiming to make healthcare safer and more effective for everyone. It consistently evolves its solutions to achieve this critical, forward-looking vision.
Medisafe has raised $53.0M across 5 funding rounds.
Medisafe has raised $53.0M in total across 5 funding rounds.
Medisafe has raised $53.0M in total across 5 funding rounds.
Medisafe's investors include Sanofi Ventures, Dudi Klein, Eight Roads Ventures, S Capital VC, Toyota Ventures, Eyal Gura, 7wireVentures, Consensus Business Group, Leumi Partners, lool ventures, Menorah Mivtachim, M Ventures.
Medisafe is a Boston-based digital health company founded in 2012 that builds a leading medication engagement platform to help patients manage complex treatment regimens through personalized reminders, interventions, and ecosystem integrations.[2][3][4] It serves patients, pharma partners, healthcare providers, and caregivers facing medication non-adherence—a crisis causing preventable health issues—by delivering AI-driven tools like Just-In-Time Interventions (JITI), Medisafe Maestro for treatment orchestration, and a Care Integration Engine, achieving 72% patient retention at 90 days versus the 34% industry average and managing over 2 billion doses for 10 million users.[1][2][5][6] With $51.6M in funding, HIPAA/GDPR compliance, and certifications like ISO 13485:2016 for medical device quality, Medisafe powers white-label solutions, Software as a Medical Device (SaMD), and rapid 90-day launches, driving 77%+ adherence improvements amid a $47B+ digital health market.[1][4][5]
Medisafe was founded in 2012 by Israeli brothers Omri Shor (current CEO) and Rotem Shor, entrepreneurs motivated by a family crisis: their diabetic father's near-fatal insulin overdose due to a medication scheduling mix-up, highlighting a widespread global issue.[3] Drawing on their skills, they launched the app as one of the first mobile health platforms on iOS and Android, initially focusing on prescription management, information access, and stakeholder collaboration.[3][5] Early traction exploded, growing from a startup to 5 million users, 250,000 reviews (4.7/5 stars), and ecosystem interfaces within years, evolving into a mature platform with behavioral AI by its 10-year mark in 2022.[3][5]
Medisafe rides the digital health adherence wave in a $47B+ industry exploding with 350K+ apps and 250 daily launches, where smartphones now enable 90% of patients to manage health—up from 35% in 2012—saving systems like the U.S. ~$7B yearly.[5][6] Timing aligns with post-pandemic connectivity demands, AI maturity (via AWS partnerships), and regulatory pushes for SaMD, positioning Medisafe as a resilient leader amid economic uncertainty by focusing on sustainable growth and pharma-centric ecosystems.[1][5] It influences the landscape by setting adherence benchmarks, fostering connected health (e.g., monoclonal antibodies for Alzheimer's), and bridging patients/providers/pharma, reducing non-adherence's $300B+ annual global cost through scalable, patient-centric tech.[1][2][6]
Medisafe's momentum—10M users, AWS AI expansions, and rapid solutions—positions it to dominate medication engagement as AI personalizes care further and ecosystems integrate deeply.[1][5][6] Trends like voice AI (VIA), behavioral science, and global pharma digital shifts will accelerate growth, potentially scaling to unicorns via more SaMD approvals and partnerships.[1][4] Its influence may evolve from app pioneer to ecosystem orchestrator, redefining adherence in an aging, chronic-disease world—solidifying its role as the patient-centric force that started with a family's scare.
Medisafe has raised $53.0M across 5 funding rounds. Most recently, it raised $30.0M Series C in February 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2021 | $30.0M Series C | Sanofi Ventures, Dudi Klein | Eight Roads Ventures, S Capital VC, Toyota Ventures, Eyal Gura, 7wireVentures, Consensus Business Group, Leumi Partners, lool ventures, Menorah Mivtachim, M Ventures, Octopus Ventures, OurCrowd, Pitango HealthTech, Qualcomm Ventures, Triventures |
| Feb 1, 2017 | $15.0M Series B | Eyal R. | Eight Roads Ventures, S Capital VC, Toyota Ventures, Eyal Gura, 7wireVentures, lool ventures, Edward Kliphuis, Pitango Venture Capital, Qualcomm Ventures, Triventures |
| Jan 13, 2015 | $6.0M Series A | Ittai Harel | Eyal Gura, 7wireVentures, lool ventures, Triventures |
| Sep 23, 2013 | $1.0M Other Equity | Avichay Nissenbaum, Michal Geva | Eyal Gura, Yadin Kaufmann, Yair Schindel |
| Sep 1, 2013 | $1.0M Seed | Chemi, Innovation Endeavors, Webtalk Ltd, Jim Lanzone |